We have been working on finalizing our new CPAP interface for market. We have a functional prototype we have been testing for months and just received the final product for market. The product arrived in beautiful form, but we have some small molding issues that will delay us for another six weeks approximately. The molding issues are straight forward and will be resolved shortly. This new CPAP interface is truly a breakthrough product and we want to be sure it is 100% before we release it to the market. We all know at least half, or more, of the people who have a CPAP system do not use it because they cannot tolerate the CPAP mask they are using. There are two major problems everyone is having with their CPAP mask. The first problem is that the mask is uncomfortable to wear. The second major problem is that too many patients can’t adequately breath using their CPAP mask. The first problem can be overcome after a few days of use, but there is no way to get use to the second problem. If a patient can’t breath adequately treatment is not going to be successful. Deltawave is designed to address all of the issues causing problems with non-compliance to treatment. We have thoroughly tested this product on ourselves and many other patients for months and months with consistent results. The Deltawave is designed to promote normal breathing throughout the entire night, which is something we have not been able to achieve with any other CPAP mask we could find. We are excited about this new product and pleased to let shareholders know we are almost there. We posted what you just read back in Nov 19, 2018. We are saying the same thing today because nothing has changed except that we have been delayed and expect to have finished product around mid-May 2019. During this time we have been able to carry on critical in-house testing with this product and we believe we have the real thing. The Deltawave is the most comfortable, quietest, and smoothest operating CPAP interface we can find. We emphasize the Deltawave is no ordinary CPAP interface. We believe we have the CPAP and NIV interface that may possibly confer additional benefits by assisting breathing difficulties in comorbidities along with sleep apnea such as, respiratory failure, COPD, and heart failure. (COPD) Chronic obstructive pulmonary disease is the third leading cause of death in the US and will continue to rise world wide by 2030. The cost of this disease in the US alone is approximately $50 billion annually. Over 90% of patients with COPD are not receiving (NIV) non-invasive ventilation therapy. We believe the Deltawave may be a good fit for patients with COPD. CPAP therapy is the main treatment for obstructive sleep apnea, but based upon Sleep Health Journal the majority of patients do not tolerate CPAP and only 23-45% continue to use CPAP on a regular basis because of issues with their face mask. According to the Sleep and Health Journal approximately one in four patients love their CPAP from the first night and use all night, every night with excellent results. The typical CPAP user averages only 4-5 hours CPAP use at night. These are the patients that are at the most severe risk. Typically, heart attacks and strokes associated with sleep apnea happen in the early morning hours. Patients wearing their CPAP for only 4-5 hours or less have already discontinued CPAP use before the time of night when the worst risk for cardiovascular events occur. A very high percentage of sleep apnea patients either reject the therapy outright or use it sparingly, risking their well being. Patients push back primarily because the interface (mask) is difficult to breathe on and uncomfortable. Tom Wood, CEO, commented, “We have spent five years designing and developing a device to overcome the primary issues of CPAP non-compliance. The Deltawave’s proprietary design allows patients to breathe normally while on CPAP, a monumental breakthrough that is expected to bring relief to many who suffer from sleep apnea.” If a CPAP interface does not deliver enough air volume to the nostrils it will take longer for the patient to take in a breath — this is an obvious fact. If it takes longer than normal to take in a breath it will disrupt the patient’s normal respiratory rate of 14 breaths per minute. Some CPAP masks can cause a patient’s normal respiratory rate of 14 to drop as low as 9 breaths per minute, or even lower because the volume of air needed is not available to the CPAP patient. It can be difficult to sleep 8 hours every night with this interrupted respiratory rate, among other unwanted conditions. The Deltawave was designed to go another direction. The head strap is never tight and it is there only to hold the interface in place. The new patent pending pillows are designed to allow adequate air flow at a slower air velocity, among other features. For all the non-compliance patients the Deltawave is expected to have a very positive impact on those who try it. Patients who use Deltawave are expected to breathe a normal 14 breaths per minute, and sleep for a full 6-8 hours every night. According to Sleep Review Magazine, Sleep Apnea Devices Market was valued at $3.8 billion in 2012 and is estimated to reach a market worth of $6.4 billion in 2019 at a compound annual growth rate of 7.8% from 2014 to 2019. The market for sleep apnea devices will exhibit tremendous growth potential in the near future, the report says. Forward-looking statements Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. No information in this press release should be construed as any indication whatsoever of the Company’s future revenues, results of operations or stock price. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Contact Information REMSleep Holdings, Inc. Tom Wood 912-590-6048 [email protected]
For the original news story, please visit https://prdistribution.com/news/shareholder-update.html.